The alopecia treatment market has been gaining major popularity over the past few years owing to the increasing incidence of alopecia across the globe. Alopecia refers to hair loss commonly known as baldness which occurs when hair follicles shrink, become dormant or stop producing new hair altogether. There are various types of alopecia condition like androgenetic alopecia, alopecia areata among others. The rising prevalence of alopecia, increasing awareness about treatment options and growing number of new treatment approvals are fueling the growth of this market.
The Global alopecia treatment market is estimated to be valued at US$ 10.2 Bn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the alopecia treatment are Stemson Therapeutics, OliX Pharmaceuticals, Inc, Pfizer Inc, Aclaris Therapeutics, Inc., Fagron, Follicum AB, Cipla Inc., Arcutis Biotherapeutics, Dr. Reddy’s Laboratories Ltd., Himalaya Wellness Company, Stemson Therapeutics, Cosmo Pharmaceuticals N.V., Equillium, Inc., Eli Lilly and Company, Concert Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. The major key players are involved in research and development of new drugs and technology to treat alopecia.
The growing demand for treatment of alopecia due to increasing number of patient pool is fueling the growth of alopecia treatment market. As per recent study the number of people affected by alopecia is increasing at an exponential rate globally. This has led to high demand for effective alopecia treatment options.
The alopecia treatment market is expanding globally with increasing awareness about treatment and availability of new treatment options. The key players are focused on expanding their presence in emerging markets like Asia Pacific and Latin America. Generic drugs availability and patent expiries of branded drugs also provide opportunities for regional and local players to enter the alopecia treatment market in various countries.
Market Drivers
Increasing stress levels among people is considered as one of the major driver for alopecia treatment market. Stress is known to be one of the major risk factor associated with alopecia conditions. With changing lifestyle and environment, stress related disorders have increased substantially over the past decade. This has led to rise in prevalence of stress-induced alopecia globally.
Current geopolitical situations are impacting the growth of the alopecia treatment market. Factors like rising political tensions and armed conflicts are adding to people's mental stress levels. Stress is a major trigger for alopecia. As geopolitical uncertainties increase around the world, so does stress and anxiety among populations. This means the demand for alopecia treatments is also rising. However, restrictions in international trade and global supply chains due to sanctions or barriers can hamper the easy availability of alopecia drugs in some regions. The market players need to diversify their manufacturing and sourcing strategies as well as consider politically stable regions for expansion to overcome such challenges. They should also explore biologics and advanced therapies like stem cell treatments to address alopecia in more effective ways. Developing affordable generic versions of popular alopecia drugs can further help expand access in emerging markets facing socioeconomic issues.
North America holds the major share of the alopecia treatment market in terms of value currently. This is due to high alopecia prevalence, strong healthcare infrastructure and spending power in the region. However, the Asia Pacific market is projected to grow the fastest during the forecast period. This is attributed to rising lifestyle diseases, growing medical tourism, increasing cosmetic consciousness and expansion of healthcare facilities in densely populated developing countries like China and India. The Middle East and Africa region is also expected to witness steady market growth owing to improving economic conditions and access to advanced treatments.
Europe also captures a notable market value share due to supportive insurance and public healthcare systems across countries. However, its market value growth may be restricted compared to other emerging regions facing fewer regulatory barriers and having larger underpenetrated patient bases. Overall, emerging markets with conducive governmental policies will attract higher investments fromalopecia drug makers in the future.
